Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.

Cancer cell - 18 Mar 2013

Roti Giovanni, Carlton Anne, Ross Kenneth N, Markstein Michele, Pajcini Kostandin, Su Angela H, Perrimon Norbert, Pear Warren S, Kung Andrew L, Blacklow Stephen C, Aster Jon C, Stegmaier Kimberly

Abstract excerpt

Notch1 is a rational therapeutic target in several human cancers, but as a transcriptional regulator, it poses a drug discovery challenge. To identify Notch1 modulators, we performed two cell-based, high-throughput screens for small-molecule inhibitors and cDNA enhancers of a NOTCH1 allele bearing a leukemia-associated mutation. Sarco/endoplasmic reticulum calcium ATPase (SERCA) channels emerged at the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to G1 Phase Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Screening Assays

Share to Receptor, Notch1

Share to Sarcoplasmic Reticulum Calcium-Transporting ATPases

Share to Small Molecule Libraries

Share to Thapsigargin

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 23434461
DOI: 10.1016/j.ccr.2013.01.015
PMCID: PMC3709972

Genes

NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.PMID 23434461Read ↗

Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Leukemia-specific delivery of mutant NOTCH1 targeted therapy.Semantic proximity Read ↗

Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth.Semantic proximity Read ↗

SERCA2 Dysfunction in Darier Disease Causes Endoplasmic Reticulum Stress and Impaired Cell-to-Cell Adhesion Strength: Rescue by MiglustatSemantic proximity Read ↗

NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.Semantic proximity Read ↗

β-Arrestins and disease-linked variants: opportunities for targeted modulation.Semantic proximity Read ↗

Novel NOTCH1-unmutated T-ALL Cell Line With Suppressed Growth by Gamma-secretase Inhibitors.Semantic proximity Read ↗

Cancer-related somatic mutations alter adenosine A1 receptor pharmacology-A focus on mutations in the loops and C-terminus.Semantic proximity Read ↗

Pharmacological disruption of the Notch transcription factor complex.Semantic proximity Read ↗

Cancer-Related Somatic Mutations in Transmembrane Helices Alter Adenosine A1 Receptor Pharmacology.Semantic proximity Read ↗

A mutation in EGF repeat-8 of Notch discriminates between Serrate/Jagged and Delta family ligands.Semantic proximity Read ↗

Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.